Pharmaceutical

(Curcumin + doxorubicin) by Immix BioPharma for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Dec 24, 2023 - 18:00
(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC).
Read the original article

Tags:

Previous Article

Mecbotamab vedotin by BioAtla for Breast Cancer: Likelihood of Approval

Next Article

(Curcumin + doxorubicin) by Immix BioPharma for Metastatic Colorectal Cancer: Li...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Flow Neuroscience shows promising results in trial of brain-stimulation headset for depression

STAT+: Flow Neuroscience shows promising results in tri...

Aug 1, 2023

DMTs are major clinical research focus for Parkinson’s disease, analysis shows

DMTs are major clinical research focus for Parkinson’s ...

Nov 13, 2024

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Biosyngen receives FDA approval to start Phase I trial ...

Sep 11, 2023